Prediction of Rhizoma Drynariae Targets in the Treatment of Osteoarthritis Based on Network Pharmacology and Experimental Verification

Figure 8

The viability of SW1353 cells after treatment with different concentrations of the aqueous extract of Rhizoma Drynariae (AERD) or luteolin, with or without 10 ng/mL IL-1β. (a) SW1353 cells were treated with different concentrations of AERD for 12 h with or without 10 ng/mL IL-1β. (b) SW1353 cells were treated with different concentrations of luteolin for 12 h with or without 10 ng/mL IL-1β. The data are derived from three independent experiments and are expressed as mean ± standard deviation ( < 0.05: increase compared with the control group;  < 0.05: decrease compared with the control group).

(a)

(b)